A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Shen Lin, MD
Peking University Cancer Hospital & Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
- Fujian Medical University - Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
- the First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
- the First People'S Hospital of Foshan
Foshan, Guangdong, China
- Cancer Center of Guangzhou Medical University
Guangzhou, Guangdong, China
- the Sixth Affiliated Hospital Sun Yat-Sen University
Guangzhou, Guangdong, China
- Cancer Hospital Affiliated To Shantou University Medical College
Shantou, Guangdong, China
- Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
- the Affiliated Hospital of Hebei University
Baoding, Hebei, China
- Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
- Xiangya Hospital Central South University
Changsha, Hunan, China
- the First People'S Hospital of Changzhou
Changzhou, Jiangsu, China
- First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
- the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
- the Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
- the First Hospital of Jilin University
Changchun, Jilin, China
- the First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
- Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
- the First Hospital of China Medical University
Shenyang, Liaoning, China
- Shaanxi Provincial People'S Hospital
Xi'an, Shaanxi, China
- Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
- Shanghai East Hospital, Tongji University
Shanghai, Shanghai Municipality, China
- Xinhua Hospital Affilliated To Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
- Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
- the Second People'S Hospital of Neijiang
Neijiang, Sichuan, China
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
- Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
- the First Affiliated Hospital - Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Sept 2021
- Primary completion
- 19 Dec 2023
- Completion
- 7 Dec 2024
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 107
- Registry id
- NCT05004350
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.